Geminin gene and protein

Details Geminin gene and protein Geminin gene and protein

1998-06-11

2003-04-15

Martinell, James (Department: 1631)

Chemistry: molecular biology and microbiology

Micro-organism, per se ; compositions thereof; proces of...

Bacteria or actinomycetales; media therefor

C435S325000, C435S320100, C536S023200, C536S023500

Reexamination Certificate

active

06548290

ABSTRACT:

BACKGROUND OF THE INVENTION
Proliferative diseases such as cancer are a leading cause of death for persons of certain age groups. Uncontrollable or abnormal cell replication is a common characteristic of cancers. Much research is performed in an attempt to determine a cause of cancer and other proliferative diseases. In addition, much effort has gone into determining ways to regulate or control cellular replication, and in particular, the mechanisms which inhibit cellular replication. A need exists to modulate, enhance or inhibit cell division and/or DNA replication.
Significant research has also been performed in the area of neurological diseases or conditions. Examples of such diseases or conditions are Parkinson's disease, Alzheimer's disease, multiple sclerosis, and patients with spinal cord injuries. Patients with neurological diseases or conditions do not have curative or effective treatment options. Scientists are attempting to determine the mechanisms controlling neural development and, in particular, ways to promote neural growth and regeneration. A need exists to promote neurogenesis or the ability to facilitate neural differentiation.
SUMMARY OF THE INVENTION
The invention relates to a protein, called Geminin, which inhibits DNA or cellular replication and promotes neural growth. The C-terminus of Geminin inhibits DNA replication and the N-terminus promotes neural growth, also referred to as neurogenesis. The Geminin protein comprises domains with specific functions. For example, the protein has a replication inhibitory domain which inhibits DNA replication. Within this replication inhibitory domain is a coiled-coil domain which is the site of protein-protein interaction. Geminin also has a domain which elicits neurogenesis. Another domain of the Geminin protein is the destruction box domain, which is responsible for degradation of the Geminin protein upon poly-ubiquitination.
Therefore, the invention encompasses the nucleic acid sequence and the encoded amino acid sequence of the entire Geminin protein, the N-terminal portion, the C-terminal portion, the replication inhibitory domain and the destruction box sequence. The invention also pertains to a nucleic acid sequence and the encoded amino acid sequence of the C-terminus or replication inhibitory domain with a mutated, deleted, or non-functional destruction box sequence. A mutated, deleted, or non-functional destruction box sequence causes a protein that is refractory to poly-ubiquitin mediated degradation.
The invention also relates to an antibody or antibody fragment which binds to a portion of the Geminin protein. An antibody can be a monoclonal or polyclonal antibody. The antibody can inhibit Geminin function or its interaction with other proteins.
The invention also pertains to a plasmid or vector comprising a nucleic acid sequence which encodes the Geminin protein or a portion thereof, as described herein. A cell or bacterial strain may also be transfected with the nucleic acid that encodes a Geminin protein or a portion thereof. Additionally, the invention relates to a fusion protein having an amino acid sequence of a Geminin protein or a portion thereof conjugated with a portion of an immunoglobulin or an antibody binding domain.
The invention includes methods for inhibiting or enhancing DNA replication in cells by administering a Geminin protein, an agonist or an antagonist thereof. Furthermore, the invention relates to methods for treating patients with proliferative diseases, including cancer, by administering the same.
The invention also includes methods for inhibiting or enhancing neural growth or neurogenesis in cells by administering the Geminin protein, agonists or antagonists thereof. Consequently, the invention also pertains to methods for treating patients with a neurological disease, disorder, or condition. Examples of such diseases, disorders, or conditions are Parkinson's disease, Alzheimer's disease, multiple sclerosis, and a patient with a spinal cord injury. Such a method embodies transfecting the nucleic acid which encodes at least a portion of the N-terminus of Geminin into embryonic ectodermal cells, maintaining the cells in conditions suitable for cell differentiation and/or cell division, and then transplanting these cells into the injured or affected neural area.


REFERENCES:
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5643873 (1997-07-01), Barrett et al.
patent: 5654276 (1997-08-01), Barrett et al.
Hillier et al, GenBank Accession No. AA447810 Jun. 4, 1997.*
Marra et al, Trends in Genetics, Jan. 1998, vol. 14, No. 1, pages unknown.*
Hudson GenBankâ Accession No. G24505 (1996) ENTREZ Release 24.0, Aug. 15, 1996).*
Hudson, GenBank Accession No. G24504 1996.*
Chitnis, et al., “Neural Induction and Neurogenesis in Amphibian Embryos,”Perspectives on Developmental Neurobiology,3(1): 3-15 (1995).
Nieuwkopp, et al., “The Further Development of the Cephalic Ganglia and Nerves.” InNormal Table of Xenopus Laevis(Daudin), P.D. Nieuwkoop, et al., eds. ((Garland Publishing, Inc.) pp. 60-73 (1994).
McGarry, T.J., et al., “Geminin, an Inhibitor of DNA Replication, Is Degraded during Mitosis”,Cell,93:1043-1053 (1998).
Kroll, K.L., et al., “Geminin, a neuralizing molecule that demarcates the future neural plate at the onset of gastrulation”,Development,125:3247-3258 (1998).
Marushige, Y., et al., “Growth Inhibition of Synchronized Trigeminal Neurinoma Cells by Nerve Growth Factor”,Anticancer Research,14:153-156 (1994).
Glotzer, M., et al., “Cyclin is degraded by the ubiquitin pathway”,Nature,349:132-138 (1991).
Nucleotide Sequence DatabaseEMBL,ID MM1165322, Accession number AA250610, Mar. 15, 1997.
Nucleotide Sequence DatabaseEMBL,ID AA544218, Accession number AA44218, Aug. 12, 1997.
Nucleotide Sequence DatabaseEMBL,ID HS1221842, Accession number AA393139, May 19, 1997.
Nucleotide Sequence DatabaseEMBL,ID HS1247813, Accession number AA447810, Jun. 10, 1997.
Chong, J.P. et al., “Purification of an MCM-containing complex as a component of the DNA replication licensing system,”Nature 375:418-421 (1995).
Harland, R.M., “Neural induction in Xenopus,” inMolecular and Cellular Approaches to Neural Development,(eds., W.M. Cowan, T.M. Jessell and S.L. Zipursky), Oxford: Oxford University Press, pp. 1-25 (1997).
Hutchinson, C.J., “The use of cell free extracts of Xenopus eggs for studying DNA replication in vitro,” In The cell cycle: a practical approach, P. Fantes and R. Brooks, eds. (Oxford: IRL Press), pp. 177-195 (1993).
Kay, B.K. and Peng, H.B.,Xenopus laevis:Practical uses in cell and molecular biology, vol. 36, L. Wilson, ed. (San Diego, California: Academic Press) (1991).
Oschwald, R. et al. “Localization of a nervous system-specific class II beta-tubulin gene inXenopus laevisembryos by whole-mount in situ hybridization,”Int J Dev Biol 35:399-405 (1991).
Schmidt, J.E. et al. “Regulation of dorsal-ventral patterning: the ventralizing effects of the novel Xenopus homobox gene Vox”Development 122:1711-21 (1996).
Amon, A. et al., “Closing the cell cycle circle in yeast: G2 cyclin proteolysis initiated at mitosis persists until the activation of G1 cyclins in the next cell cycle,”Cell 77:1037-1050 (1994).
Aristarkhov, A. et al., E2-C, a cyclin selective ubiquitin carrier protein required for the destruction of mitotic cyclins, Proceedings of the National Academy of Sciences (USA) 93:4294-4299 (1996).
Berger, B. et al., “Predicting coiled coils by use of pairwise residue correlations,” Proceedings of the National Academy of Sciences (USA) 92:8259-8263 (1995).
Blow, J.J. and Laskey, R.A., “Initiation of DNA replication in nuclei and purified DNA by a cell-free extract of Xenopus eggs,”Cell 47:577-587 (1986).
Blow, J.J. et al., “A role for the nuclear envelope in controlling DNA replication within the cell cycle,”Nature 332:546-548 (1998).
Brandeis, M., and Hunt, T., “The Proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase,” EMBO Journal 15 (1996).
Brown, K.D. et al., “Cyclin-like accumulation and loss of the putative k

Affiliated with

Also associated with

Rating

Geminin gene and protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Geminin gene and protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Geminin gene and protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3083701